have now a release. Thanks, By should access press Heidi . earnings you to the copy of
you this morning's relations the to go not, presentation. the of access and our website If investor release press do please section to
include begin do let Company’s today, we remind you Statements. Before the that me remarks Forward-Looking
in filings. statements subject to and of Company's the beyond are including differ are those numerous risk many materially SEC to statement. Forward-looking projected. undertakes Company's described update uncertainties the results may time-to-time The from which forward-looking any The no risks and Company's publicly control, from uncertainties, obligation Company
earnings Slide expenses, reconciliation of per Additionally, on X, the as with operating right refer these measures non-GAAP most measures, operating our financial to that, discussed which is margin, included non-GAAP website. our measures operating again on press specifically Five. into and I'll share. and financial income, first A we release, in income With directly on results Slide our GAAP available jump is comparable quarter net
basis profit we XX.X% Science segment the sales preliminary slightly, quarter on reported Xth. first was revenues margin of gross business January of results in million flat excluding foreign the XXXX. in the announced and decreased in as decrease XX essentially improved quarter earlier rates total a sales the revenues was quarter. XXXX impact total as represented where diagnostic line about fiscal to of X.X% for This today, consolidated X% in up first $XX.X the our by had about with or $XX.X a fiscal our we decline, compared the were As points. million This decline of decline currency exchange Despite X%, driven Life
The net of share the net and million results quarter of the in These in litigation operating fiscal basis, combine GAAP organizational a of share the or quarter and approximately to phase income in year's increased benefit a litigation non-GAAP initiatives. of $X.XX compared in in and full On Tax $XXX,XXX quarter, quarter. GAAP non-GAAP savings of included respectively XX% earnings Reform and improvement increased XX.X% in U.S. in negative million last year our XX%, million earnings XX% first of actions operating million, earnings quarter volume increase non-GAAP cost ago. reduction to well As $X.X was increased entirely well and consolidation down ongoing R&D largely as pricing and our in operating On lower sales an were offset or related as result results operating $X.X taken XXXX, as a quarter as compared and of activities XXXX, reflected $XX.X or management reflecting expense clinical business improvement impact quarter discipline. Lower year-over-year, about basis, adjusted of diagnostics. in and income Life of Science XXXX in to lower in place CMV points the from XX% income streamlining the marketing expenses earnings fiscal of and $X.X reorganization first This million, in XXXX expense to commissions. lower, that also was trial was basis expense the actions G&A basis, reflect including XXX primarily XXXX. over GAAP first Sales took approximately expenses fiscal costs restructuring respectively. million On results. $X.X $XX.X charges XX% XXXX. per per
despite fiscal both slide, income segment our next our results the first operating software improvement, of units quarter operating highlighting XXXX Turning posted operating revenues. compared to to margin the and business
decline H. pressure experienced in pressure pylori molecular significant related C products, declines revenue with revenues overall which related combined This in As X% of products mentioned previously, driven the diagnostic pricing notably and Diff, X% diagnostics. quarter. to $XX.X GI revenue in decline volume in million, an declined predominantly by drove including an XX%
Continued ago a of growth million declines. a offset certain availability products, respiratory Diagnostic up these and compared non-GAAP year led basis. to $X.X products X.X% in partially on to which X% operating better were income increased
lower sales XX% previously trial Operating activity reduction, with basis. as mentioned, clinical venous operating R&D blood led a costs ago, from were the expense and well year both as XX%, quarter commissions supported in non-GAAP diagnostics expense testing regaining up lower As for margins on associated claims. lower from the a
at quarter other At strong offset after a exceeded Life and XX% the activity consecutive Science order than expected of operating operating XX.X%, as a by quarter a $X.X basis. strong result regions overall the both molecular fiscal for the our customers quarter million, in China income to result in particularly growth XXXX. reagent Non-GAAP Europe revenues and note. decline flat were had in side, strong year-over-year in significantly margin increased closing and Science Science Life XXXX consolidation about Turning $XX.X and a in Non-GAAP on significantly reagent restructuring on demand activities Science cost the boosted the new Life fiscal had quarter customer the to veterans. the Life products products, million second immune new lower of softer as
Turning our for to Slide XXXX. We discussed updated guidance full-year Seven.
providing outlook are remainder and reexamination. this quarter XXXX for guidance first results cause we on to Our of did the us updated based our reexamine fiscal
In to business. minute, in that softer factors color guidance We now the high-single diagnostics are Life declines low-single in Science Revenue to provide more the Science will a lower X% consolidated is in order diagnostics little of growth a digit updated of major expectations. in and driving our these revenue underlying some flat expected expectations business QX in now than in on based patterns low-double are growth digits as growth Jack segment. revenue digit guidance well Life as the providing the just
remains for is our guidance, fiscal XX% for operating guidance primarily Company XX% margin approximately into are operating also the expectation operating approximately GAAP adjusting representing Non-GAAP expense the range. We margin carryover litigation XXXX. now margin
tax also our expected businesses jurisdictions. Well Science Life result expected performance Our rate Life margin the in stronger a lower than with the QX, guidance been as contribution between margin was in pressure tax profit margin and largely diagnostics of lower match updated a year has to mix operating Science and in progresses. diagnostics
for the XX%. GAAP a XX.X% balance year XX.X% $X.XX reflecting to tax guidance of the guidance net to EPS Accordingly per our and in rate of remains tax of of Our changes, $X.XX guidance the share. full-year remains $X.XX EPS to resulting effect at $X.XX our Non-GAAP these
important in to our that comparisons fiscal second business is for demand particularly diagnostics products in for respiratory of strong it difficult Lastly, will in make quarter related the note XXXX QX.
year. is it turn in implies that, the revenue to I'll backend weighted And that with As a result, guidance our over Jack. growth
